Methcathinone is a synthetic stimulant closely related to methamphetamine and chemically derived from cathinone, the active compound found in the khat plant. It acts on the brain in a similar way to methamphetamine, flooding it with dopamine and norepinephrine to produce intense but short-lived euphoria and energy. On the street, it goes by names like “cat,” “jeff,” and “mulka.” It has been a Schedule I controlled substance in the United States since 1993, meaning it is considered to have high abuse potential and no accepted medical use.
How Methcathinone Works in the Brain
Methcathinone is what pharmacologists call a “transporter substrate.” Rather than simply blocking the recycling of feel-good brain chemicals the way cocaine does, it actively forces dopamine and norepinephrine out of nerve cells and into the spaces between them. This mechanism is essentially the same one methamphetamine uses. The result is a rapid surge in alertness, energy, confidence, and pleasure.
Its strongest effects are on norepinephrine (the chemical behind the fight-or-flight response), followed by dopamine (the reward chemical). It has very little effect on serotonin, which distinguishes it from drugs like MDMA. In practical terms, this means methcathinone produces a stimulant high that feels more like meth than ecstasy: intensely energizing and euphoric, but without much of the emotional warmth or empathy associated with serotonin-heavy drugs.
Short-Term Effects
The immediate effects of methcathinone mirror those of other powerful stimulants. Users typically experience a rush of euphoria, increased alertness, and a sense of heightened confidence. Heart rate and blood pressure rise. Appetite drops. Sleep becomes difficult or impossible for hours after a dose.
At higher doses or with repeated use, the picture gets darker. Agitation, anxiety, and paranoia are common. Some users develop full-blown psychosis, including hallucinations and aggressive or erratic behavior. Hyperthermia (dangerously elevated body temperature) is a known risk and has been linked to fatalities involving synthetic cathinones. The high tends to be relatively brief, which encourages compulsive redosing, a pattern that sharply increases the risk of overdose and psychological crisis.
A Unique Neurological Danger: Manganese Poisoning
Methcathinone carries a risk that most other stimulants do not. When it is manufactured at home using a common “kitchen” recipe, potassium permanganate is used as an oxidizing agent. This leaves manganese as a contaminant in the final product. People who inject homemade methcathinone (often called “ephedrone” in Eastern Europe) can accumulate manganese in their brains over time, particularly in the basal ganglia, the region that controls movement.
The result is a condition called manganese-induced parkinsonism. It resembles Parkinson’s disease but has its own distinct features. Affected users develop muscle stiffness, slowed movement, impaired facial expressions, and difficulty with fine motor tasks like writing (handwriting progressively shrinks, a symptom called micrographia). A characteristic “rooster gait,” walking on tiptoes with the chest pushed forward, is one of the hallmarks. Speech becomes monotone and may deteriorate to the point of being nearly unintelligible.
Perhaps most disturbing are the neurological symptoms that go beyond movement. Many people with manganese encephalopathy develop a forced, involuntary smile resembling a grimace, along with episodes of uncontrollable laughing or crying that don’t match their actual emotions. Cognitive decline is common. Unlike Parkinson’s disease, this damage responds poorly to standard Parkinson’s medications, because the underlying brain structures affected are different. Much of the damage is considered irreversible. Cases have been documented extensively in Eastern Europe, particularly in Poland, the Baltic states, and Russia, where homemade ephedrone injection has been widespread.
History and Origins
Methcathinone was first synthesized in the late 1920s by German and French chemists. It was not originally intended as a recreational drug. It was a byproduct of research into ephedrine synthesis. In the 1930s and 1940s, the Soviet Union used it clinically as an antidepressant. By the 1950s, the American pharmaceutical company Parke-Davis explored marketing it as both an antidepressant and an appetite suppressant, and a U.S. patent on the production process was granted in 1957. Neither application ever reached the commercial market.
Recreational use began to spread in the Soviet Union during the 1970s and 1980s. It eventually reached the United States in the early 1990s, prompting the DEA to place it into Schedule I in 1993. Internationally, methcathinone is controlled under Schedule I of the United Nations Convention on Psychotropic Substances. It also serves as the chemical backbone for many newer synthetic cathinones (sometimes called “bath salts”), several of which have been independently scheduled as they appeared on the market.
Methcathinone vs. Methamphetamine
The two drugs are structurally similar. Methcathinone is essentially methamphetamine with an extra oxygen atom attached, forming what chemists call a ketone group. This small chemical difference shortens the duration of the high and slightly alters the balance of brain chemicals affected, but the core experience is comparable. Both drugs force dopamine and norepinephrine out of neurons with similar potency, and both carry serious risks of addiction, cardiovascular damage, and psychosis.
The key practical difference is the source. Methamphetamine is most often produced in large-scale clandestine labs using precursor chemicals that are now tightly regulated. Methcathinone, by contrast, can be synthesized from over-the-counter cold medications containing pseudoephedrine using relatively simple chemistry. This accessibility is what made it popular in regions of Eastern Europe and, for a period, in parts of the rural United States. The simplicity of production is also what introduces the manganese contamination risk described above.
Addiction and Withdrawal
Methcathinone’s short duration of action makes it particularly prone to binge use. Users often redose repeatedly in a single session, chasing the initial rush as it fades. This pattern accelerates the development of tolerance, meaning more of the drug is needed to achieve the same effect, and increases the likelihood of dependence.
Withdrawal from methcathinone follows the general pattern seen with stimulants: an initial “crash” involving extreme fatigue, depression, and increased appetite, followed by a longer period of low mood, irritability, difficulty concentrating, and strong cravings. The psychological dependence can be intense. There are no medications specifically approved for treating methcathinone addiction, so treatment typically focuses on behavioral therapy and managing symptoms during the withdrawal period.